Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells

ÖZKAN, TÜLİN; Hekmatshoar, Yalda; ERTAN BOLELLİ, TUĞBA; Hidavat, Andry; Beksac, Mcral; Aki-Yalcin, Esin; Yalcin, Ismail; SUNGUROĞLU, ASUMAN

doi:10.2174/1871520618666171229222534

Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells

ÖZKAN T., Hekmatshoar Y., ERTAN BOLELLİ T., Hidavat A. N., Beksac M., Aki-Yalcin E., ...Daha Fazla

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, cilt.18, sa.11, ss.1521-1530, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 18 Sayı: 11
Basım Tarihi: 2018
Doi Numarası: 10.2174/1871520618666171229222534
Dergi Adı: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1521-1530
Anahtar Kelimeler: CML, K562, imatinib resistance, benzamide, apoptosis, CHRONIC MYELOID-LEUKEMIA, BIOLOGICAL EVALUATION, BENZOXAZOLES, IMATINIB, INHIBITORS, MECHANISM
Ankara Üniversitesi Adresli: Evet

Özet

Background: The tyrosine kinase inhibitor, imatinib, used as a first line treatment in Chronic Myeloid Leukemia (CML) patients, may lead to resistance and failure to therapy. Novel combinations of imatinib with other drugs is a strategy to improve treatment efficiency.